The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability.

[1]  J. Moffat,et al.  Identification of RNF168 as a PML nuclear body regulator , 2016, Journal of Cell Science.

[2]  Susumu Y. Imanishi,et al.  A new vertebrate SUMO enzyme family reveals insights into SUMO-chain assembly , 2015, Nature Structural &Molecular Biology.

[3]  C. Lima,et al.  Structural basis for catalytic activation by the human ZNF451 SUMO E3 ligase , 2015, Nature Structural &Molecular Biology.

[4]  H. de Thé,et al.  PML nuclear bodies: regulation, function and therapeutic perspectives , 2014, The Journal of pathology.

[5]  M. Mann,et al.  Uncovering Global SUMOylation Signaling Networks in a Site-Specific Manner , 2014, Nature Structural &Molecular Biology.

[6]  I. Matic,et al.  Proteome-Wide Identification of SUMO2 Modification Sites , 2014, Science Signaling.

[7]  A. Pichler,et al.  SUMO Rules: Regulatory Concepts and Their Implication in Neurologic Functions , 2013, NeuroMolecular Medicine.

[8]  Daniel C. Factor,et al.  The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein , 2013, Oncogene.

[9]  P. Thibault,et al.  Targeted Identification of SUMOylation Sites in Human Proteins Using Affinity Enrichment and Paralog-specific Reporter Ions* , 2013, Molecular & Cellular Proteomics.

[10]  F. Melchior,et al.  Sumoylation: a regulatory protein modification in health and disease. , 2013, Annual review of biochemistry.

[11]  A. Dejean,et al.  Arkadia, a Novel SUMO-Targeted Ubiquitin Ligase Involved in PML Degradation , 2013, Molecular and Cellular Biology.

[12]  Xiwen Cheng,et al.  Post-translational modifications of PML: consequences and implications , 2013, Front. Oncol..

[13]  H. de Thé,et al.  Acute promyelocytic leukemia, arsenic, and PML bodies , 2012, The Journal of cell biology.

[14]  John V Heymach,et al.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. , 2012, Cancer research.

[15]  Yu‐Min Lin,et al.  A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. , 2011, Cancer Cell.

[16]  Zhu Chen,et al.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure , 2010, Nature Reviews Cancer.

[17]  Jian-Hua Tong,et al.  Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML , 2010, Science.

[18]  M. Scheffner,et al.  E6AP promotes the degradation of the PML tumor suppressor , 2009, Cell Death and Differentiation.

[19]  J. Palvimo,et al.  ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator. , 2008, Journal of molecular biology.

[20]  M. Mann,et al.  Ubc9 sumoylation regulates SUMO target discrimination. , 2008, Molecular cell.

[21]  M. Lei,et al.  Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway , 2008, Nature Cell Biology.

[22]  M. Tatham,et al.  RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation , 2008, Nature Cell Biology.

[23]  Rosa Bernardi,et al.  Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies , 2007, Nature Reviews Molecular Cell Biology.

[24]  Ming-Jing Hwang,et al.  Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. , 2006, Molecular cell.

[25]  Pier Paolo Pandolfi,et al.  The mechanisms of PML-nuclear body formation. , 2006, Molecular cell.

[26]  Jingde Zhu,et al.  Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3 , 2005, Oncogene.

[27]  T. Sixma,et al.  The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type , 2004, Nature Structural &Molecular Biology.

[28]  P. Pandolfi,et al.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.

[29]  A. Dejean,et al.  The Nucleoporin RanBP2 Has SUMO1 E3 Ligase Activity , 2002, Cell.

[30]  P. Pandolfi,et al.  Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression , 2001, The Journal of experimental medicine.

[31]  E. Yeh,et al.  Identification of Three Major Sentrinization Sites in PML* , 1998, The Journal of Biological Chemistry.

[32]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[33]  X. Le,et al.  Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. , 1997, Carcinogenesis.

[34]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. , 1997, Pharmacology & therapeutics.

[35]  F. Melchior,et al.  A Small Ubiquitin-Related Polypeptide Involved in Targeting RanGAP1 to Nuclear Pore Complex Protein RanBP2 , 1997, Cell.

[36]  S. Knauer,et al.  Differential regulation of PML-RARα stability by the ubiquitin ligases SIAH1/SIAH2 and TRIAD1. , 2012, The international journal of biochemistry & cell biology.